CN104703592A - 治疗轻度和中度阿尔茨海默病的方法 - Google Patents
治疗轻度和中度阿尔茨海默病的方法 Download PDFInfo
- Publication number
- CN104703592A CN104703592A CN201380051206.0A CN201380051206A CN104703592A CN 104703592 A CN104703592 A CN 104703592A CN 201380051206 A CN201380051206 A CN 201380051206A CN 104703592 A CN104703592 A CN 104703592A
- Authority
- CN
- China
- Prior art keywords
- day
- subject
- phenoxy
- hydrochloride
- achei
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Neurology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Psychiatry (AREA)
- Obesity (AREA)
- Hospice & Palliative Care (AREA)
- Hematology (AREA)
- Emergency Medicine (AREA)
- Pain & Pain Management (AREA)
- Anesthesiology (AREA)
- Endocrinology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Dermatology (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910466681.3A CN110292638A (zh) | 2012-10-05 | 2013-10-02 | 治疗轻度和中度阿尔茨海默病的方法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261710229P | 2012-10-05 | 2012-10-05 | |
| US61/710,229 | 2012-10-05 | ||
| PCT/US2013/062964 WO2014055588A1 (en) | 2012-10-05 | 2013-10-02 | Treatment of mild and moderate alzheimer's disease |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201910466681.3A Division CN110292638A (zh) | 2012-10-05 | 2013-10-02 | 治疗轻度和中度阿尔茨海默病的方法 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN104703592A true CN104703592A (zh) | 2015-06-10 |
Family
ID=49354960
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201380051206.0A Pending CN104703592A (zh) | 2012-10-05 | 2013-10-02 | 治疗轻度和中度阿尔茨海默病的方法 |
| CN201910466681.3A Pending CN110292638A (zh) | 2012-10-05 | 2013-10-02 | 治疗轻度和中度阿尔茨海默病的方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201910466681.3A Pending CN110292638A (zh) | 2012-10-05 | 2013-10-02 | 治疗轻度和中度阿尔茨海默病的方法 |
Country Status (16)
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019190822A1 (en) | 2018-03-28 | 2019-10-03 | Vtv Therapeutics Llc | Crystalline forms of [3-(4- {2-butyl-1-[4-(4-chloro-phenoxy)-phenyl]-1h-imidazol-4-yl} -phenoxy)-propyl]-diethyl-amine |
| WO2019190823A1 (en) * | 2018-03-28 | 2019-10-03 | Vtv Therapeutics Llc | Pharmaceutically acceptable salts of [3-(4- {2-butyl-1-[4-(4-chlorophenoxy)-phenyl]-1h-imidazol-4-yl} -phenoxy)-propyl]-diethyl-amine |
| JP7464591B2 (ja) | 2018-10-10 | 2024-04-09 | ブイティーブイ・セラピューティクス・エルエルシー | [3-(4-{2-ブチル-1-[4-(4-クロロ-フェノキシ)-フェニル]-1h-イミダゾール-4-イル}-フェノキシ)-プロピル]-ジエチル-アミンの代謝産物 |
| WO2020086388A1 (en) * | 2018-10-22 | 2020-04-30 | Vtv Therapeutics Llc | Glucokinase activator compositions for the treatment of cognitive impairment |
| JP7327788B2 (ja) * | 2019-08-06 | 2023-08-16 | 学校法人福岡大学 | 糖化産物生成抑制剤及び医薬組成物 |
| CN114957470B (zh) * | 2021-11-12 | 2023-01-17 | 深圳市人民医院 | 靶向rage的纳米抗体及其应用 |
| US11648235B1 (en) | 2022-12-30 | 2023-05-16 | Cantex Pharmaceuticals, Inc. | Treatment of glioblastoma |
Family Cites Families (50)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5585344A (en) | 1984-03-19 | 1996-12-17 | The Rockefeller University | Liver-derived receptors for advanced glycosylation endproducts and uses thereof |
| EP0352581A3 (de) | 1988-07-28 | 1990-07-04 | F. Hoffmann-La Roche Ag | Aethylendiaminmonoamid-Derivate |
| US5166214A (en) | 1988-12-05 | 1992-11-24 | Du Pont Merck Pharmaceutical Company | Use of imidazoles for the treatment of atherosclerosis |
| US5840294A (en) | 1993-03-29 | 1998-11-24 | Queen's University At Kingston | Method for treating amyloidosis |
| ES2170104T3 (es) | 1993-10-01 | 2002-08-01 | Merrell Pharma Inc | Inhibidores de la produccion de proteinas de beta-amiloide. |
| US5817626A (en) | 1995-03-14 | 1998-10-06 | Praecis Pharmaceuticals Incorporated | Modulators of beta-amyloid peptide aggregation |
| US5939526A (en) | 1995-03-21 | 1999-08-17 | Ludwig Institute For Cancer Research | Isolated RAGE-1 derived peptides which complex with HLA-B7 molecules and uses thereof |
| WO1997026913A1 (en) | 1996-01-26 | 1997-07-31 | The Trustees Of Columbia University In The City Of New York | A POLYPEPTIDE FROM LUNG EXTRACT WHICH BINDS AMYLOID-β PEPTIDE |
| US5864018A (en) | 1996-04-16 | 1999-01-26 | Schering Aktiengesellschaft | Antibodies to advanced glycosylation end-product receptor polypeptides and uses therefor |
| WO1997039121A1 (en) | 1996-04-16 | 1997-10-23 | Schering Aktiengesellschaft | Advanced glycosylation end-product receptor peptides and uses therefor |
| EP1184370B1 (en) | 1996-07-22 | 2005-09-14 | Novo Nordisk A/S | Compounds with growth hormone releasing properties |
| US6790443B2 (en) | 1996-11-22 | 2004-09-14 | The Trustees Of Columbia University In The City Of New York | Method for treating symptoms of diabetes |
| US7258857B2 (en) | 1996-11-22 | 2007-08-21 | The Trustees Of Columbia University In The City Of New York | Rage-related methods for treating inflammation |
| US6555651B2 (en) | 1997-10-09 | 2003-04-29 | The Trustees Of Columbia University In The City Of New York | Ligand binding site of rage and uses thereof |
| US5962535A (en) | 1997-01-17 | 1999-10-05 | Takeda Chemical Industries, Ltd. | Composition for alzheimer's disease |
| US6268479B1 (en) | 1997-03-12 | 2001-07-31 | The Trustees Of Columbia University In The City Of New York | Intracellular amyloid-beta peptide binding (ERAB) polypeptide |
| US7101838B2 (en) | 1997-08-05 | 2006-09-05 | The Trustees Of Columbia University In The City Of New York | Method to prevent accelerated atherosclerosis using (sRAGE) soluble receptor for advanced glycation endproducts |
| US6323218B1 (en) | 1998-03-11 | 2001-11-27 | The General Hospital Corporation | Agents for use in the treatment of Alzheimer's disease |
| US6274615B1 (en) | 1998-03-25 | 2001-08-14 | South Alabama Medical Science Foundation | Method for delaying the onset of alheimer's disease and for treatment or delaying the onset of other amyloidosis-related diseases/disorders |
| US6465422B1 (en) | 1998-04-17 | 2002-10-15 | The Trustees Of Columbia University In The City Of New York | Method for inhibiting tumor invasion or spreading in a subject |
| US5981168A (en) | 1998-05-15 | 1999-11-09 | The University Of British Columbia | Method and composition for modulating amyloidosis |
| AU765142B2 (en) | 1998-06-01 | 2003-09-11 | Ortho-Mcneil Pharmaceutical, Inc. | Method for treating neurodegenerative disorders |
| AU1199600A (en) | 1998-10-02 | 2000-04-26 | Board Of Trustees Of The University Of Illinois, The | Estrogen receptor ligands |
| US6753150B2 (en) | 1998-10-05 | 2004-06-22 | The Trustees Of Columbia University In The City Of New York | Method for determining whether a compound is capable of inhibiting the interaction of a peptide with rage |
| AU765719B2 (en) | 1998-10-06 | 2003-09-25 | Trustees Of Columbia University In The City Of New York, The | Extracellular novel rage binding protein (EN-RAGE) and uses thereof |
| JP2003507013A (ja) | 1999-08-13 | 2003-02-25 | ザ・トラスティーズ・オブ・コランビア・ユニバーシティー・イン・ザ・シティー・オブ・ニューヨーク | βシートフィブリルのRAGEへの結合を阻害する方法及びその結果 |
| US20010051642A1 (en) | 2000-04-17 | 2001-12-13 | Kyunghye Ahn | Method for treating Alzheimer's disease |
| US6613801B2 (en) | 2000-05-30 | 2003-09-02 | Transtech Pharma, Inc. | Method for the synthesis of compounds of formula I and their uses thereof |
| US6825164B1 (en) | 2000-08-14 | 2004-11-30 | The Trustees Of Columbia University In The City Of New York | Method to increase cerebral blood flow in amyloid angiopathy |
| CA2440042C (en) | 2001-03-05 | 2011-09-27 | Transtech Pharma, Inc. | Carboxamide derivatives as therapeutic agents |
| CN1235583C (zh) | 2001-03-05 | 2006-01-11 | 特兰斯泰克制药公司 | 用作治疗剂的苯并咪唑衍生物 |
| EP1482931B1 (en) | 2002-03-05 | 2011-10-19 | TransTech Pharma, Inc. | Mono- and bicyclic azole derivatives that inhibit the interaction of ligands with rage |
| JP2006522128A (ja) | 2003-04-03 | 2006-09-28 | メルク エンド カムパニー インコーポレーテッド | 代謝調節型グルタミン酸受容体−5のモジュレーターとしての4環イミダゾール誘導体 |
| CN102584813B (zh) | 2003-05-14 | 2016-07-06 | Ngc药物公司 | 化合物及其在调节淀粉样蛋白β中的用途 |
| CN1805743A (zh) * | 2003-05-20 | 2006-07-19 | 特兰斯泰克制药公司 | 用作逆转淀粉样变性及其他与之相关疾病的rage拮抗剂 |
| SI1703902T1 (sl) | 2004-01-05 | 2011-02-28 | Merz Pharma Gmbh & Co Kgaa | Memantin za zdravljenje blage do zmerne Alzheimerjeve bolezni |
| DE102004050176A1 (de) | 2004-09-20 | 2006-03-23 | Universität Duisburg-Essen | Optoelektronisches Bauelement und Verfahren zum Steuern von Tunnelelektronenströmen durch Photonen |
| US7601745B2 (en) | 2004-09-27 | 2009-10-13 | 4Sc Ag | Heterocyclic NF-kB inhibitors |
| US20070135437A1 (en) | 2005-03-04 | 2007-06-14 | Alsgen, Inc. | Modulation of neurodegenerative diseases |
| EP1707203A1 (en) * | 2005-04-01 | 2006-10-04 | Bioprojet | Treatment of parkinson's disease obstructive sleep apnea, dementia with lewy bodies, vascular dementia with non-imidazole alkylamines histamine H3- receptor ligands |
| WO2006124897A2 (en) | 2005-05-13 | 2006-11-23 | Lexicon Genetics Incorporated | Methods and compositions for improving cognition |
| US20080153811A1 (en) | 2006-11-07 | 2008-06-26 | Joseph Barbosa | Methods of Treating Cognitive Impairment and Dementia |
| CN101663280A (zh) * | 2007-04-05 | 2010-03-03 | 转化技术制药公司 | [3-(4-{2-丁基-1-[4-(4-氯-苯氧基)-苯基]-1h-咪唑-4-基}-苯氧基)-丙基]-二乙基-胺的晶型ⅰ和ⅱ |
| JP2010523559A (ja) * | 2007-04-05 | 2010-07-15 | トランス テック ファーマ,インコーポレイテッド | [3−(4−{2−ブチル−1−[4−(4−クロロ−フェノキシ)−フェニル]−1h−イミダゾール−4−イル}−フェノキシ)−プロピル]−ジエチルアミンの結晶形態 |
| US20100254983A1 (en) * | 2007-06-07 | 2010-10-07 | Ann Marie Schmidt | Uses of rage antagonists for treating obesity and related diseases |
| US20090221554A1 (en) * | 2008-02-28 | 2009-09-03 | Zenyaku Kogyo Kabushiki Kaisha | Method of treating cognitive impairment |
| BRPI1012697A2 (pt) | 2009-04-27 | 2016-03-29 | High Point Pharmaceuticals Llc | derivados imidazo[1,2-a]piridina substituídos, composições farmacêuticas, e métodos de uso como inibidores da b-secretase |
| CA2772797C (en) | 2009-09-30 | 2018-09-25 | Transtech Pharma, Inc. | Substituted imidazole derivatives |
| TWI510241B (zh) | 2010-02-18 | 2015-12-01 | Vtv Therapeutice Llc | 苯基-雜芳基衍生物及其使用方法 |
| WO2012061927A1 (en) * | 2010-11-08 | 2012-05-18 | Alectos Therapeutics, Inc. | Selective glycosidase inhibitors and uses thereof |
-
2013
- 2013-10-02 KR KR1020157011366A patent/KR20150064743A/ko not_active Ceased
- 2013-10-02 SG SG11201502210VA patent/SG11201502210VA/en unknown
- 2013-10-02 EA EA201590687A patent/EA201590687A1/ru unknown
- 2013-10-02 MX MX2015003732A patent/MX377733B/es active IP Right Grant
- 2013-10-02 AU AU2013327450A patent/AU2013327450B2/en active Active
- 2013-10-02 NZ NZ705813A patent/NZ705813A/en unknown
- 2013-10-02 CN CN201380051206.0A patent/CN104703592A/zh active Pending
- 2013-10-02 CA CA2886785A patent/CA2886785C/en active Active
- 2013-10-02 CN CN201910466681.3A patent/CN110292638A/zh active Pending
- 2013-10-02 IN IN3734DEN2015 patent/IN2015DN03734A/en unknown
- 2013-10-02 WO PCT/US2013/062964 patent/WO2014055588A1/en not_active Ceased
- 2013-10-02 JP JP2015535750A patent/JP6566868B2/ja active Active
- 2013-10-02 BR BR112015007641A patent/BR112015007641A8/pt active Search and Examination
- 2013-10-02 EP EP13776676.2A patent/EP2903606A1/en not_active Withdrawn
- 2013-10-02 HK HK15107776.8A patent/HK1207004A1/xx unknown
- 2013-10-02 NZ NZ739521A patent/NZ739521A/en unknown
- 2013-10-02 SG SG10201702648YA patent/SG10201702648YA/en unknown
- 2013-10-22 US US14/059,529 patent/US9717710B2/en active Active
-
2015
- 2015-03-12 IL IL237730A patent/IL237730B/en active IP Right Grant
-
2017
- 2017-06-23 US US15/631,203 patent/US20170326113A1/en not_active Abandoned
-
2018
- 2018-05-16 AU AU2018203434A patent/AU2018203434A1/en not_active Abandoned
-
2019
- 2019-01-08 US US16/242,757 patent/US20190142803A1/en not_active Abandoned
- 2019-05-23 JP JP2019096786A patent/JP6894940B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| US20170326113A1 (en) | 2017-11-16 |
| CA2886785C (en) | 2022-06-07 |
| MX2015003732A (es) | 2015-09-23 |
| MX377733B (es) | 2025-03-11 |
| JP2015535850A (ja) | 2015-12-17 |
| BR112015007641A8 (pt) | 2018-04-03 |
| CA2886785A1 (en) | 2014-04-10 |
| JP6566868B2 (ja) | 2019-08-28 |
| AU2013327450B2 (en) | 2018-07-12 |
| IN2015DN03734A (cg-RX-API-DMAC7.html) | 2015-09-18 |
| JP6894940B2 (ja) | 2021-06-30 |
| EP2903606A1 (en) | 2015-08-12 |
| BR112015007641A2 (pt) | 2017-07-04 |
| US20140100218A1 (en) | 2014-04-10 |
| US20190142803A1 (en) | 2019-05-16 |
| WO2014055588A1 (en) | 2014-04-10 |
| JP2019163301A (ja) | 2019-09-26 |
| AU2018203434A1 (en) | 2018-06-07 |
| CN110292638A (zh) | 2019-10-01 |
| KR20150064743A (ko) | 2015-06-11 |
| NZ739521A (en) | 2019-06-28 |
| AU2013327450A1 (en) | 2015-05-14 |
| NZ705813A (en) | 2018-02-23 |
| IL237730B (en) | 2018-10-31 |
| EA201590687A1 (ru) | 2015-09-30 |
| US9717710B2 (en) | 2017-08-01 |
| HK1207004A1 (en) | 2016-01-22 |
| SG11201502210VA (en) | 2015-04-29 |
| SG10201702648YA (en) | 2017-04-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019163301A (ja) | 軽度および中等度アルツハイマー病の処置 | |
| US20250082651A1 (en) | Ganaxolone for use in treating genetic epileptic disorders | |
| US12036190B2 (en) | Methods and compositions for the treatment of cytoplasmic glycogen storage disorders | |
| KR102486434B1 (ko) | 바독솔론 메틸 또는 이의 유사체를 사용하는 알포트 증후군의 치료 방법 | |
| EP2663304B1 (en) | Combination therapy | |
| AU2006226811B2 (en) | Dosage regimen for the treatment of a traumatic brain injury with progesterone | |
| US8455468B2 (en) | Methods for the treatment of a traumatic central nervous system injury | |
| US9937182B2 (en) | Therapeutic strategies for the treatment of preeclampsia | |
| Ueki et al. | Long-term safety and efficacy of alogliptin, a DPP-4 inhibitor, in patients with type 2 diabetes: a 3-year prospective, controlled, observational study (J-BRAND Registry) | |
| Pringle et al. | Severe bradycardia due to interaction of timolol eye drops and verapamil | |
| JP2018138572A (ja) | 疾患および障害を検出、治療、および予防するための組成物および方法 | |
| Walters et al. | Early clinical experience with the novel NMDA receptor antagonist CNS 5161 | |
| HK40009571A (zh) | 治疗轻度和中度阿尔茨海默病的方法 | |
| US20250114363A1 (en) | Pharmaceutical composition comprising allopurinol, febuxostat, or a pharmaceutically acceptable salt thereof for preventing or treating cardiovascular disease of subject having high serum uric acid level | |
| Zaremba-Pechmann et al. | Ronald Dahl, Michael Engel b, Daniel Dusser c, David Halpin d, Huib AM Kerstjens e | |
| CN105250268B (zh) | 厄贝沙坦组合物及其在制备治疗急性肾损伤的药物中的应用 | |
| Clough et al. | Effect of inflammatory mediators on the developing micro circulation of the rabbit ear chamber | |
| WO2020169041A1 (zh) | 含氨氯地平、氯噻酮和醛固酮受体拮抗剂的药物组合物 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C53 | Correction of patent of invention or patent application | ||
| CB02 | Change of applicant information |
Address after: North Carolina Applicant after: vTv Therapeutics LLC Address before: North Carolina Applicant before: TRANSTECH PHARMA, Inc. |
|
| COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: Free format text: CORRECT: APPLICANT; FROM: TRANSFORMATION TECHNOLOGY PHARMA, LLC TO: VTV THERAPEUTICS LLC |
|
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C41 | Transfer of patent application or patent right or utility model | ||
| CB02 | Change of applicant information |
Address after: North Carolina Applicant after: VTVX Holdings I LLC Address before: North Carolina Applicant before: VTV THERAPEUTICS LLC |
|
| COR | Change of bibliographic data | ||
| TA01 | Transfer of patent application right |
Effective date of registration: 20151130 Address after: North Carolina Applicant after: VTV THERAPEUTICS LLC Address before: North Carolina Applicant before: VTVX Holdings I LLC |
|
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1207004 Country of ref document: HK |
|
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20150610 |
|
| RJ01 | Rejection of invention patent application after publication | ||
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: WD Ref document number: 1207004 Country of ref document: HK |